Login / Signup

Subgroup analysis in haematologic malignancies phase III clinical trials: A systematic review.

Nerea Báez-GutiérrezHéctor Rodríguez-RamalloSandra Flores-MorenoLaila Abdel-Kader Martín
Published in: British journal of clinical pharmacology (2020)
The subgroup claims reported in haematology RCTs lack credibility, even when the claims are strong. Information about subgroup difference should be interpreted cautiously.
Keyphrases
  • phase iii
  • clinical trial
  • open label
  • health insurance
  • phase ii
  • double blind
  • placebo controlled
  • healthcare
  • health information